Analyst firms · Oppenheimer · NKTR

Oppenheimer NKTR price target and rating history

Nektar Therapeutics (NKTR) · Health Care

Oppenheimer rates Nektar Therapeutics (NKTR) Outperform with a $6 price target, as of its latest action on Mar 14, 2025. It has published 3 rating actions on NKTR since November 2021, including 2 upgrades and 0 downgrades. Across 5 firms with a NKTR price target in the last 12 months, the median target is $102.

Current rating
Outperform
Price target
$6
Median target, all firms
$102
Actions on NKTR
3

Oppenheimer price target on NKTR

$21$14$620222023202420252026
Oppenheimer price target on NKTR, each point a stated target, November 2021 to March 2025.

Every Oppenheimer rating on NKTR

How other firms rate NKTR

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
UBSNeutral$53Oct 12, 2026
Leerink PartnersOutperform$130Oct 12, 2026
Raymond JamesMkt PerformOct 9, 2026
Canaccord GenuityBuy$153Jul 22, 2026
WedbushNeutral$70Mar 24, 2026
TD CowenBuyMar 17, 2026
William BlairOutperformFeb 10, 2026
CitigroupBuy$102Nov 26, 2025

Questions about Oppenheimer and NKTR

What is Oppenheimer's price target for NKTR?
Oppenheimer's latest stated price target for Nektar Therapeutics (NKTR) is $6, from its action on Mar 14, 2025.
What is Oppenheimer's rating on NKTR?
Oppenheimer rates NKTR Outperform, a bullish rating, as of Mar 14, 2025.
When did Oppenheimer last change its view on NKTR?
On Mar 14, 2025, Oppenheimer upgrades to Outperform from Perform, price target $6.
How does Oppenheimer's NKTR target compare with other analysts?
Across 5 firms with a NKTR price target in the last 12 months, the median target is $102.

More NKTR rating histories

All Oppenheimer ratingsNKTR news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.